Core Insights - aTyr Pharma is preparing for a meeting with the FDA in mid-April 2026 to discuss the Phase 3 EFZO-FIT™ study results for efzofitimod in treating pulmonary sarcoidosis [1][2] Group 1: Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][4] - The company's lead therapeutic candidate, efzofitimod, is a novel biologic immunomodulator aimed at treating interstitial lung disease (ILD) [3][4] Group 2: Study Results - The Phase 3 EFZO-FIT™ study involved 268 patients with symptomatic pulmonary sarcoidosis [2] - Although the study did not meet its primary endpoint of reducing mean daily oral corticosteroid dose at week 48, clinical benefits were observed in several efficacy parameters, including: - Improvement in the King's Sarcoidosis Questionnaire (KSQ)-Lung score (p=0.0479) - Improvement in the Fatigue Assessment Scale score (p=0.0226) - Improvement in the KSQ-General Health score (p=0.0197) - Complete steroid withdrawal with KSQ-Lung score improvement (p=0.0196) [2] Group 3: Mechanism and Additional Studies - Efzofitimod selectively modulates activated myeloid cells through neuropilin-2, resolving inflammation without immune suppression and potentially preventing fibrosis progression [3] - In addition to the EFZO-FIT™ study, efzofitimod is also being investigated in the Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD [3]